4D Molecular Therapeutics (FDMT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

4D Molecular Therapeutics (FDMT) Healthcare & Pipeline Overview

4D Molecular Therapeutics, Inc. is a pioneering clinical-stage gene therapy company specializing in adeno-associated virus vectors, targeting critical therapeutic areas such as ophthalmology, cardiology, and pulmonology, with a robust pipeline of clinical candidates.

What Is the Investment Thesis for FDMT?

The company is currently advancing three product candidates in clinical trials, with potential market sizes in the billions for each therapeutic area. The ongoing collaboration with established partners such as Roche and uniQure provides additional validation and resources for the company’s research efforts. With a market capitalization of $726M and a focus on high-impact therapeutic areas, 4D Molecular is well-positioned to capitalize on the growing demand for gene therapies. However, investors should be mindful of the inherent risks associated with clinical-stage biotechnology companies, including regulatory hurdles and the need for successful trial outcomes.

Based on FMP financials and quantitative analysis

FDMT Key Highlights

Market capitalization of $726M reflects strong investor interest in gene therapy innovations.

• Currently advancing three product candidates in Phase 1/2 clinical trials, targeting significant unmet medical needs.
• Research collaborations with major industry players like Roche enhance development capabilities and market credibility.
• High beta of 2.76 indicates significant volatility, typical for clinical-stage biotech firms.
• Profit margin of -182.3% highlights the early-stage nature of the company's operations and investment in R&D.

Who Are FDMT's Competitors?

FDMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FDMT's Key Strengths?

Innovative gene therapy platform with proprietary technology.

• Strong clinical pipeline with multiple candidates in development.
• Strategic collaborations with leading pharmaceutical companies.

What Are FDMT's Weaknesses?

High operational costs typical of clinical-stage biotechnology firms.

• Negative profit margins indicating early-stage financial challenges.
• Dependence on successful clinical trial outcomes for future growth.

What Could Drive FDMT Stock Higher?

FDMT catalyst: Results from ongoing Phase 1/2 clinical trials for 4D-125, 4D-110, and 4D-310 are anticipated, which could significantly impact the company's valuation.

• Strategic collaborations with Roche and uniQure continue to enhance research capabilities and market positioning.
• Potential IND submissions for additional product candidates could expand the clinical pipeline.

What Are the Key Risks for FDMT?

Negative return on equity (-36.8%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles could delay clinical trial timelines and product approvals.
• Dependence on successful trial outcomes poses a risk to future revenue generation.
• Market competition from established biotechnology firms may impact market share.

What Are the Growth Opportunities for FDMT?

• Growth opportunity 1: The global ophthalmology market is projected to reach $54.2 billion by 2026, driven by increasing prevalence of eye disorders. 4D-125 and 4D-110 target significant conditions like X-linked retinitis pigmentosa and choroideremia, respectively, which have high unmet needs. Successful clinical trials could position 4D as a leader in this lucrative market segment.
• Growth opportunity 2: The cardiology market, anticipated to grow to $67.5 billion by 2027, presents a significant opportunity for 4D-310, which targets Fabry disease. With a focus on innovative gene therapies, 4D could capture a substantial share of this growing market, particularly as awareness and diagnosis of rare genetic conditions increase.
• As advancements in gene therapy continue, 4D's innovative approach could provide a competitive edge, potentially transforming treatment paradigms for cystic fibrosis patients.
• Growth opportunity 4: Collaborations with major pharmaceutical companies like Roche and uniQure enhance 4D's research capabilities and access to resources. These partnerships can accelerate the development timeline for product candidates, potentially leading to earlier market entry and revenue generation.
• Growth opportunity 5: As regulatory environments become more favorable for gene therapies, 4D Molecular Therapeutics stands to benefit from expedited approval processes. The company's focus on high-impact therapeutic areas aligns with regulatory priorities, potentially facilitating faster access to market.

What Threats Does FDMT Face?

• Intense competition from other biotechnology firms and emerging startups.
• Regulatory hurdles and potential changes in healthcare policies.
• Market volatility impacting funding and investment in biotechnology.

What Are FDMT's Competitive Advantages?

• Proprietary gene therapy platform utilizing adeno-associated virus vectors.
• Strong partnerships with established companies enhance credibility and resources.
• Focus on high-impact therapeutic areas with significant unmet medical needs.

What Does FDMT Do?

Founded in 2013 and headquartered in Emeryville, California, 4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company dedicated to developing innovative therapies using adeno-associated virus (AAV) vectors. The company's mission is to address significant unmet medical needs in the fields of ophthalmology, cardiology, and pulmonology. Over the years, 4D Molecular has established a diverse portfolio of gene therapy product candidates, with three currently in clinical trials: 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease. In addition to these candidates, the company is advancing two Investigational New Drug (IND) candidates: 4D-150, targeting wet age-related macular degeneration, and 4D-710, aimed at treating cystic fibrosis lung disease. 4D Molecular Therapeutics has formed strategic research and collaboration arrangements with notable partners such as uniQure, CRF, Roche, and CFF, enhancing its research capabilities and clinical development efforts. With a workforce of 227 employees, the company is positioned to leverage its expertise in gene therapy to deliver transformative treatments for patients suffering from debilitating diseases.

What Products and Services Does FDMT Offer?

• Develops gene therapy product candidates using adeno-associated virus vectors.
• Focuses on three therapeutic areas: ophthalmology, cardiology, and pulmonology.
• Currently advancing multiple product candidates through clinical trials.
• Collaborates with leading pharmaceutical companies to enhance research and development.
• Aims to address significant unmet medical needs in genetic diseases.
• Utilizes innovative technologies to improve treatment efficacy and patient outcomes.

How Does FDMT Make Money?

• Generates revenue through partnerships and collaborations with pharmaceutical companies.
• Plans to monetize successful product candidates upon regulatory approval.
• Focuses on research and development investments to drive innovation and pipeline expansion.
• Aims to leverage intellectual property through licensing agreements in the future.

What Industry Does FDMT Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in gene therapy and personalized medicine. The global gene therapy market is projected to reach approximately $13.3 billion by 2026, with a CAGR of 34.3% from 2021 to 2026. 4D Molecular Therapeutics operates within this dynamic landscape, focusing on ophthalmology, cardiology, and pulmonology—areas with substantial unmet medical needs. The competitive landscape includes established biotechnology firms and emerging startups, all vying for market share in the burgeoning gene therapy sector. 4D's innovative approach and strategic collaborations position it favorably against competitors.

Who Are FDMT's Key Customers?

• Patients suffering from genetic diseases in ophthalmology, cardiology, and pulmonology.
• Healthcare providers and institutions seeking innovative treatment options.
• Pharmaceutical partners collaborating on research and development initiatives.

Over the past six months, 4D Molecular Therapeutics insiders filed 43 SEC Form 4 transactions — 25 sales and 18 purchases. On net that is roughly 1.3M shares acquired (about $11.5M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: 4D Molecular Therapeutics

Revenue for 4D Molecular Therapeutics came in at $3.8M during Q2 FY2026, a 24.1% improvement versus the preceding quarter. The company recorded a net loss of $72.9M, with diluted EPS of $-1.04. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, FDMT averaged $-0.68 in diluted EPS.

FDMT Valuation & Market Position

With a $726M market cap, 4D Molecular Therapeutics sits in the small-cap segment of the market. Analyst price targets span from $32.00 to $32.00, with a consensus of $32.00. At the current price of $13.88, that implies approximately 131% upside potential. Relative to its peer group, FDMT's quantitative score of 29/100 is below the peer average of 82/100.

Return on equity for 4D Molecular Therapeutics stands at -36.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.6%, the inverse of the P/E and a quick read on earnings relative to price.

4D Molecular Therapeutics's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.51 places it in the grey zone, a middle ground that warrants monitoring.

4D Molecular Therapeutics has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 16.5% above estimates on average.

Company Profile

4D Molecular Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO David H. Kirn. FDMT has traded publicly since 2020.

FDMT Financials

FDMT Latest News

FDMT Analyst Consensus

FDMT MoonshotScore

What Investors Ask About 4D Molecular Therapeutics (FDMT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources